White Blood Cell Count in Women: Relation to Inflammatory Biomarkers, Haematological Profiles, Visceral Adiposity, and Other Cardiovascular Risk Factors

Mahdieh Abbasalizad Farhangi1,2, Seyyed-Ali Keshavarz3, Mohammadreza Eshraghian4, Alireza Ostadrahimi5, Ali-Akbar Saboor-Yaraghi2,3

1Department of Community Nutrition, School of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran; 2Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, 3Department of Nutrition and Biochemistry, School of Public Health, 4Department of Biostatistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; 5Nutrition Research Center, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran

ABSTRACT

The role of white blood cell (WBC) count in pathogenesis of diabetes, cardiovascular disease, and obesity-related disorders has been reported earlier. Recent studies revealed that higher WBC contributes to atherosclerotic progression and impaired fasting glucose. However, it is unknown whether variations in WBC and haematologic profiles can occur in healthy obese individuals. The aim of this study is to further evaluate the influence of obesity on WBC count, inflammatory biomarkers, and metabolic risk factors in healthy women to establish a relationship among variables analyzed. The sample of the present study consisted of 84 healthy women with mean age of 35.56±6.83 years. They were categorized into two groups based on their body mass index (BMI): obese group with BMI >30 kg/m² and non-obese group with BMI <30 kg/m².

We evaluated the relationship between WBC and platelet count (PLT) with serum interleukin 6 (IL-6), C-reactive protein (CRP), angiotensin II (Ang II), body fat percentage (BF %), waist-circumference (WC), and lipid profile. WBC, PLT, CRP, and IL-6 in obese subjects were significantly higher than in non-obese subjects (p< 0.05). The mean WBC count in obese subjects was 6.4±0.3 (×10⁹/L) compared to 4.4±0.3 (×10⁹/L) in non-obese subjects (p=0.035). WBC correlated with BF% (r=0.31, p=0.004), CRP (r=0.25, P=0.03), WC (r=0.22, p=0.04), angiotensin II (r=0.24, p=0.03), triglyceride (r=0.24, p=0.03), and atherogenic index of plasma (AIP) levels (r=0.3, p=0.028) but not with IL-6. Platelet count was also associated with WC and waist-to-hip ratio (p<0.05). Haemoglobin and haematocrit were in consistent relationship with LDL-cholesterol (p<0.05). In conclusion, obesity was associated with higher WBC count and inflammatory parameters. There was also a positive relationship between WBC count and several inflammatory and metabolic risk factors in healthy women.

Key words: Angiotensin II; C-reactive protein; Interleukin 6; Obesity; White blood cell count

INTRODUCTION

Recent epidemiological studies revealed a positive relationship between cardiovascular disease and inflammatory markers (1). White blood cell (WBC) count, as one of the major components of inflammatory process, plays an important role in pathogenesis of insulin resistance and cardiovascular disease (2). The positive relationship between WBC count, insulin resistance, hypertension, and cardiovascular disease has been observed in several studies (1-3) whereas it is unknown whether these variations can occur in healthy obese individuals. Pro-inflammatory cytokines, such as interleukin 6 (IL-6) and interleukin 8 (IL-8), are important inducers of WBC production (4). It can be speculated that the elevated amount of these cytokines
is responsible for higher WBC count in diabetes or cardiovascular disease. Adipose tissue is a great source of inflammatory factors, such as IL-6 and C-reactive protein (CRP), which also are well-established markers of systemic inflammation (5). Certainly, there has been an enormous interest in the identification of the relationship between WBC count and these inflammatory factors in obese persons with higher fat stores, who are at greater risk of hypertension or complicating cardiovascular disorders (3). Angiotensin II has recently been proposed as a novel pro-inflammatory mediator released by adipose tissue and plays an important role in vasoconstriction and production of inflammatory factors, such as IL-6, IL-8, and vascular cell adhesion molecule (6,7). To our knowledge, no studies have yet evaluated the relationship of cytokines, such as IL-6, CRP, and angiotensin II, with WBC and haematological parameters in obesity. Therefore, in this case-control study, we investigated the relationship between WBC count, haematological profile, and inflammatory factors, including CRP, IL-6, and angiotensin II with fat mass, waist-circumference, and metabolic risk factors of cardiovascular disease in women.

MATERIALS AND METHODS

Study subjects

We examined 84 healthy volunteer women aged 35.56±6.83 years. The subjects were recruited by invitation letters distributed in different parts of Tabriz city. All subjects provided written informed consent prior to participation in the study. Demographic and medical characteristics of subjects were obtained through appropriate questionnaire. The questionnaire included information about age, marital status, smoking habits, medication, and disease status. Information on physical activity was obtained through International Physical Activity Questionnaire (IPAQ) (8). Exclusion criteria of the study subjects were as follows: taking any hormone-replacement therapy, history of hypertension, thyroid dysfunction, hepatic or renal disease, any disease known to influence immune system, and being pregnant or lactating. The research protocol was approved by the Ethics Committee of Human Experimentation of the Tehran University of Medical Sciences (TUMS-Project number 89-04-27-11869).

Anthropometric parameters

Weight was measured by calibrated Seca scale (Itin Scale Co., Inc., Germany) with the precision of 0.1 g and height by a cotton ruler. BMI was calculated as weight (kg)/(height in m)². The waist-circumference was measured above the iliac crest at the natural waistline, and the hip measurement was taken at the largest area of the natural hip-line. Waist-to-hip ratio (WHR) was also calculated based on waist and hip measurements. Body fat was measured by bioelectrical impedance analysis (Human-IM Plus; DS Dietosystem, Milan, Italy).

Biochemical parameters

After an overnight fasting (10-12 hours), venous blood samples (10.0 mL) were collected at 8:30-9:30 am in the morning. Three mL of blood samples was immediately transferred to ethylenediaminetetraacetate (EDTA) specimen bottles for measurement of haematological parameters. The remaining blood was put into a dry tube for serum extraction and analysis of biochemical profile. Total and differential WBC and haematologic profiles were determined using an automatic cell counter (Drew Scientific, Excell-18; Minnesota, USA). Blood sugar was determined by glucose oxidase-peroxidase (GOD-POD) method, using a kit (Pars-Azmoon; Tehran, Iran). Total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) were analyzed by enzymatic colorimetric method (Pars-Azmoon, Tehran, Iran). Serum low-density lipoprotein cholesterol (LDL-C) was determined by Friedwald formula: LDL-cholesterol=TC-(HDL+TG)/5 (9). Atherogenic index of plasma (AIP) was defined as Log (Triglycerides/HDL-cholesterol) (10). High-sensitivity C-reactive protein (hs-CRP) was measured by ELISA method (DRG Instruments GmbH, Germany). The inter- and intra-assay coefficients of variation (CV) for hs-CRP were <4.1% and <7.5% respectively. IL-6 levels were assayed with a commercial enzyme-linked immunosorbent assay (Quantikine IL-6 Immunoassay; e-Bioscience, San Diego, CA, USA). Each assay was performed with recombinant IL-6 standards according to the manufacturer’s protocol. This assay has a dynamic range of 2 to 200 pg/mL and a sensitivity of 4 pg/mL. Serum angiotensin II was also measured by ELISA method (Enzo, Life Science Inc.). The inter- and intra-assay coefficients of variation (CV) for this assay were <7.5% and <7.3% respectively.

Statistical analysis

The data were analyzed using standard statistical methods provided by SPSS software (version 17, SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used for verifying the hypothesis of normal distribution; all data were normally dis-
Farhangi MA et al. White blood cell count and inflammatory biomarkers in women

Table 1. Physical and biochemical characteristics of study subjects (mean±SD)

| Variable                  | BMI >30 (kg/m²) (n=44) | BMI <30 (kg/m²) (n=40) | p value |
|---------------------------|-------------------------|-------------------------|---------|
| Age (years)               | 36.6±6.0                | 34.1±7.7                | 0.183   |
| Weight (kg)               | 83.4±9.0                | 62.3±9.0                | <0.001  |
| Height (m)                | 1.6±0.1                 | 1.6±0.0                 | NS      |
| BMI (kg/m²)               | 33.7±3.4                | 24.5±3.5                | <0.001  |
| WC (cm)                   | 96.3±6.7                | 79.5±8.4                | <0.001  |
| WHR                       | 0.8±0.1                 | 0.7±0.1                 | <0.001  |
| Body fat (%)              | 44.2±7.4                | 31.9±7.1                | <0.001  |
| PA (Met-min/week)         | 1342.7±1504.4           | 1506.2±1122.6           | NS      |
| FBS (mmol/L)              | 4.5±0.9                 | 4.2±0.1                 | 0.03    |
| TG (mmol/L)               | 1.6±0.6                 | 1.3±0.5                 | <0.001  |
| TC (mmol/L)               | 4.3±1.1                 | 3.8±0.7                 | 0.03    |
| LDL-C (mmol/L)            | 2.1±0.9                 | 1.2±0.6                 | NS      |
| HDL-C (mmol/L)            | 1.4±0.2                 | 1.3±0.1                 | NS      |
| AIP                       | 0.02±0.1                | -0.04±0.1               | <0.01   |
| CRP (mg/L)                | 9.6±5.0                 | 7.5±4.2                 | 0.027   |
| Ang II (ng/mL)            | 2.0±1.0                 | 2.2±1.2                 | NS      |
| IL-6 (pg/mL)              | 30.1±20.0               | 28.9±27.6               | 0.047   |

AIP=Atherogenic index of plasma; Ang II=Angiotensin II; BMI=Body mass index; CRP=C-reactive protein; FBS=Fasting blood sugar; HDL-C=High-density lipoprotein cholesterol; IL-6=Interleukin 6; LDL-C=Low-density lipoprotein cholesterol; NS=Not significant; PA=Physical activity; TC=Total cholesterol; TG=Triglyceride; WC= Waist-circumference; WHR= Waist-to-hip ratio.

RESULTS

The main physical and biochemical features of the subjects are presented in Table 1. Serum FBS, TG, TC, and AIP in subjects with BMI >30 kg/m² were significantly higher than those with BMI <30 kg/m². In addition, obese subjects had significantly higher hs-CRP and IL-6 concentrations (p<0.05). Comparison of haematological parameters between groups is shown in Table 2. Significantly higher levels of WBC, lymphocytes, granulocytes, PLT and lower levels of haemoglobin (HGB) were observed in obese subjects compared to non-obese subjects. The WBC count showed a significant positive relationship with body fat (%), CRP, Ang II, waist-circumference, and AIP (Figure 1). These relationships remained significant, even after adjusting for the confounding effect of physical activity (Table 3). Platelet count was also positively associated with WC and WHR (Figure 2). There was also a positive relationship between WBC, TG, and AIP and between LDL-C, HGB and haematocrit (HCT) (Table 4). These findings suggest that higher WBC and PLT count is related to higher risk of metabolic syndrome or atherogenic profile in obesity.

DISCUSSION

This study demonstrates that total and differential white blood cell counts are higher in obese compared to non-obese women. Physical activity influences the circulating effect of inflammatory cytokines and WBC. Exercise in adults is associated with lower levels of C-reactive protein and WBC (11,12). In our study, WBC was positively associated with percentage of body fat, CRP, and angiotensin II, independent of physical activity score. This suggested that correlation between WBC count and fat mass (13-16) could be mediated partially by inflammatory biomarkers. To our knowledge, it is the first report of WBC’s relationship with inflammatory factors, especially angiotensin II in obesity.

Adipose tissue functions as an endocrine organ with metabolic activities. Adipose tissue produces and releases a variety of inflammatory factors and adipokines as well as cytokines and chemokines, which have been implicated as active participants in the development of insulin resistance and cardiovascular disease (5). CRP, as an acute-phase protein which originates in the liver as well as adipose tissue, has many pathophysiological roles in low-grade inflammation in obesity (17). WBC count
increases in inflammation. Systemic low-grade inflammatory response in obesity is associated with higher WBC counts and two- to three-fold increase in the systemic concentrations of CRP and IL-6 (18). IL-6 by itself further increases the production of CRP in obesity (19,20). This elevated amount of CRP is taken up by WBC, promotes migration of WBC into arterial wall, and activates the complement system and foam cell production (21). An increased CRP level is in parallel of elevated WBC production, and this mechanism can partially explain the positive relationship between these two parameters.

We also found a positive relationship between WBC and angiotensin II (p<0.05). This can also

| Table 2. Haematological parameters of study subjects |
|----------------|----------------|----------------|----------------|
| Variable       | BMI >30 (kg/m²) (n=44) | BMI <30 (kg/m²) (n=40) | Normal range | p value |
| Total WBC (×10⁹/L) | 6.4±0.3          | 4.4±0.3         | 4-11          | 0.035   |
| Lymphocytes (×10⁹/L) | 2.3±0.7          | 2.1±0.5         | 1-4           | 0.042   |
| Granulocytes (×10⁹/L) | 3.9±1.1          | 3.4±0.9         | 2-7.7         | 0.043   |
| MID (×10⁹/L) | 0.1±0.1          | 0.1±0.1         | 0.1-1.1       | NS      |
| RBC (×10¹²/L) | 4.4±0.3          | 4.5±0.3         | 3.9-5.6       | NS      |
| HCT (Proportion of 1.0) | 0.4±0.1        | 0.4±0.0         | 0.3-0.5       | NS      |
| HGB (g/L) | 125.1±10.4       | 130.1±9.5       | 120-160       | 0.026   |
| MCHC (g/L) | 329.8±10.1       | 332.9±8.5       | 320-360       | NS      |
| MCV (fl) | 86.2±8.7         | 87.9±5.7        | 82-98         | NS      |
| PLT (×10⁹/L) | 271.4±61.4       | 244.6±59.3      | 140-400       | 0.047   |

HCT=Haematocrit; HGB=Haemoglobin; MCHC=Mean corpuscular haemoglobin concentration; MCV=Mean corpuscular volume; NS=Not significant; PLT=Platelet count; RBC=Red blood cell; WBC=White blood cell; MID=Minimum inhibitory dilution

Figure 1. Relation of white blood cell count with selected anthropometric and inflammatory parameters (A: r=0.31, p=0.004; B: r=0.25, p=0.034; C: r=0.243, p=0.037; D: r=0.226, p=0.04)
be explained by the pro-inflammatory role of this molecule; accumulating evidence suggests that angiotensin II mediates its effects by increasing the pro-inflammatory cytokine production, such as IL-6 and IL-8 (6); these two cytokines are potent inducers of WBC production (4). It has been shown that inhibition of angiotensin II production is associated with reduction in WBC count (22). More interestingly, the link between elevated WBC count and hypertension, which has been reported in previous studies (23,24), may be directly related to the inflammatory and vasoconstrictor effect of angiotensin II.

Platelet counts in our obese individuals are significantly higher than in non-obese individuals. This finding is consistent with the findings of Kutluturk et al. (25) who evaluated the relationship between platelet count and metabolic risk factors of cardiovascular disease in obesity. There is an ongoing debate on whether obesity is accompanied with platelet activation. Higher concentrations of adipose tissue originating inflammatory markers may contribute to atherogenesis and thrombosis through its effects on platelet activation (26). In our study, higher CRP and IL-6 concentrations in obese individuals may be responsible for elevated platelet count in this group.

The WBC count was associated with triglyceride levels and atherogenic index of plasma as a strong predictor of various clinical and biochemical markers of CVD, especially smaller size of LDL particle (27). This result was consistent with the findings of Ohs-hita et al. (4) and Targher et al. (28). They reported that WBC count is associated with components of metabolic syndrome, such as BMI, WHR, and triglyceride. A positive relationship was also found between LDL cholesterol concentrations and haemoglobin or haematocrit levels. This result agreed with the study of Shimakawa et al. (29) and Tomoko et al. (30) reporting strong positive relationship between serum total cholesterol and haemoglobin (p<0.01 and p<0.002 respectively); the authors suggested that haemoglobin and haematocrit are associated with the risk factors of cardiovascular disease.

| Variable          | r   | p value |
|-------------------|-----|---------|
| Body fat (%)      | 0.5 | <0.001  |
| CRP (mg/L)        | 0.3 | 0.05    |
| Ang II (pg/mL)    | 0.3 | 0.049   |
| WC (cm)           | 0.3 | 0.02    |

Ang II=Angiotensin II; CRP=C-reactive protein; WC=Waist-circumference

**Table 3. Predictors of WBC in partial correlation analysis (controlling for the effect of physical activity)**

**Table 4. Relationship among haematological parameters and metabolic characteristics**

| Variable          | WBC (×10⁹/L) | HGB (g/L) | HCT (Proportion of 1.0) | PLT (×10⁹/L) |
|-------------------|--------------|-----------|-------------------------|--------------|
| FBS (mmol/L)      | 0.1 (NS)     | -0.1 (NS) | 0.1 (NS)                | -0.1 (NS)    |
| TG (mmol/L)       | 0.2 (0.03)   | -0.1 (NS) | -0.1 (NS)               | 0.1 (NS)     |
| TC (mmol/L)       | 0.1 (NS)     | 0.1 (NS)  | 0.2 (NS)                | -0.1 (NS)    |
| LDL-C (mmol/L)    | 0.1 (NS)     | 0.2 (0.05)| 0.3 (0.01)              | 0.1 (NS)     |
| HDL-C (mmol/L)    | 0.1(NS)      | 0.1 (NS)  | -0.1 (NS)               | 0.1 (NS)     |
| AIP               | 0.3 (0.028)  | -0.1 (NS) | -0.1 (NS)               | 0.2 (NS)     |

AIP=Atherogenic index of plasma; FBS=Fasting blood sugar; HCT=Haematocrit; HDL-C=High-density lipoprotein cholesterol; LDL-C=Low-density lipoprotein cholesterol; NS=Not significant; PLT=Platelet count; TC=Total cholesterol; TG=Triglyceride; WBC=White blood cell; Values expressed as r with p values in parentheses
Limitations

The present study had several limitations. First, the case-control nature of the study lacks information about the causal relationship between variables. This needs to be elucidated in future prospective studies. Second, we did not assess leptin level in our study. It has been suggested that relation of body fat and WBC count may be mediated by leptin (15). Circulating leptin concentrations increase in obesity (31). Several studies reported the in-vitro effects of leptin in proliferation of stem cells and WBC production (32) and that leptin potentiates platelet aggregation and activation in obesity (33,34). Therefore, further studies regarding the role of leptin in developing abnormal WBC or platelet production in obesity are desirable. Third, this study was carried out only in women and not in men; therefore, the results may not be generalized for total population.

Conclusions

In our study, obese women had higher WBC, platelet count, and inflammatory biomarkers compared to non-obese women. This could represent higher risk of disorders associated with cardiovascular disease or metabolic syndrome in obesity. It was also found that WBC was associated with inflammatory markers, suggesting that higher WBC count in obesity may be mediated by inflammatory factors.

ACKNOWLEDGEMENTS

This work was supported by a grant from Research Undersecretary of Tehran University of Medical Sciences (Grants no. 11869). We are grateful to the study participants who gave their time and efforts.

REFERENCES

1. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy—Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002;40:1761-8.
2. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia 2002;45:42-8.
3. Karthikeyan VJ, Lip GY. White blood cell count and hypertension. J Hum Hypertens 2006;20:310-2.
4. Ohshita K, Yamane K, Hanafusa M, Mori H, Mito K, Okubo M et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004;27:491-6.
5. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
6. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005;25:1213-29.
7. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4:43-55.
8. International Physical Activity Questionnaire. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)—Short and Long Forms, 2005. 15 p.
9. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
10. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34:583-8.
11. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 2002;162:1286-92.
12. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002;13:561-8.
13. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-61.
14. Pratley RE, Wilson C, Bogardus C. Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender. Obes Res 1995;3:563-71.
15. Wilson CA, Bekele G, Nicolson M, Ravussin E, Pratley RE. Relationship of the white blood cell count to body fat: role of leptin. Br J Haematol 1997;99:447-51.
16. Zaldivar F, McMurray RG, Nemet D, Galassetti P, Mills PJ, Cooper DM. Body fat and circulating leukocytes in children. Int J Obes (Lond) 2006;30:906-11.
17. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting
insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002;155:65-71.

18. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005;98:1154-62.

19. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005;69:29-35.

20. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.

21. Maier W, Altweg LA, Corti R, Gay S, Hersberger M, Maly FE et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005;111:1355-61.

22. Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract 2010;87:117-25.

23. Shankar A, Klein BE, Klein R. Relationship between white blood cell count and incident hypertension. Am J Hypertens 2004;17:233-9.

24. Friedman GD, Selby JV, Quesenberry CP, Jr. The leukocyte count: a predictor of hypertension. J Clin Epidemiol 1990;43:907-11.

25. Kutluturk F, Tanyolac S, Azezli A, Orhan Y. Association between platelet count and metabolic risk factors in overweight and obese women. Endocr Abstr 2009;20:473.

26. Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G et al. Platelet counts and platelet activation markers in obese subjects (Clinical Study). Mediators Inflamm 2008. 6 p. (doi: 10.1155/2008/834153)

27. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004;50:1184-8.

28. Targher G, Seidell JC, Tonoli M, Muggeo M, De Sandre G, Cigolini M. The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. J Intern Med 1996;239:435-41.

29. Shimakawa T, Bild DE. Relationship between hemoglobin and cardiovascular risk factors in young adults. J Clin Epidemiol 1993;46:1257-66.

30. Temte JL. Elevation of serum cholesterol at high altitude and its relationship to hematocrit. Wilderness Environ Med 1996;7:216-24.

31. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.

32. Cioffi JA, Shafer AW, Zupancic TJ, Smith-Gbur J, Mikhail A, Platika D et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med 1996;2:585-9.

33. Nakata M, Yada T, Soejima N, Murayama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetics 1999;48:426-9.

34. Konstantinides S, Schäfer K, Koschnick S, Loksutten DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001;108:1533-40.